Fungal-induced inflammation and nasal polyps

Eugene B. Kern, David A. Sherris, Hirohito Kita, Jens U. Ponikau

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Fungi are present in the mucus of chronic rhinosinusitis (CRS) patients and normal healthy controls. Fungi (especially Alternaria) induce the production of cytokines (IL-13 and IL-5) crucial for the eosinophilic inflammation. This immune response occurred only in CRS patients but not in healthy controls. Fungi induce an eosinophilic tissue airway inflammation in mammals (mice), which is in contrast to a neutrophilic response to bacteria. Fungi can induce an eosinophilic airway inflammation and congestion in patients. Eosinophils, in vivo, target fungi in the mucus with CRS and nasal polyps. Fungal antigens with a molecular weight of 61 kilodaltons (kDa) cause activation and degranulation of human eosinophils via the beta-2 integrin on the CD11b receptor. Clinically, antifungal drugs can reduce nasal polyps, improve computed tomography (CT) scans, and decrease levels of interleukin-5 (IL-5) and markers of eosinophilic inflammation. However, data between different antifungal applications and different outcome measures are conflicting.

Original languageEnglish (US)
Title of host publicationNasal Polyposis: Pathogenesis, Medical and Surgical Treatment
PublisherSpringer Berlin Heidelberg
Pages95-101
Number of pages7
ISBN (Print)9783642114113
DOIs
StatePublished - 2010

Fingerprint

Nasal Polyps
Fungi
Inflammation
Interleukin-5
Mucus
Eosinophils
Fungal Antigens
Integrin beta Chains
Alternaria
Interleukin-13
Mammals
Molecular Weight
Tomography
Outcome Assessment (Health Care)
Cytokines
Bacteria
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kern, E. B., Sherris, D. A., Kita, H., & Ponikau, J. U. (2010). Fungal-induced inflammation and nasal polyps. In Nasal Polyposis: Pathogenesis, Medical and Surgical Treatment (pp. 95-101). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-642-11412-0_11

Fungal-induced inflammation and nasal polyps. / Kern, Eugene B.; Sherris, David A.; Kita, Hirohito; Ponikau, Jens U.

Nasal Polyposis: Pathogenesis, Medical and Surgical Treatment. Springer Berlin Heidelberg, 2010. p. 95-101.

Research output: Chapter in Book/Report/Conference proceedingChapter

Kern, EB, Sherris, DA, Kita, H & Ponikau, JU 2010, Fungal-induced inflammation and nasal polyps. in Nasal Polyposis: Pathogenesis, Medical and Surgical Treatment. Springer Berlin Heidelberg, pp. 95-101. https://doi.org/10.1007/978-3-642-11412-0_11
Kern EB, Sherris DA, Kita H, Ponikau JU. Fungal-induced inflammation and nasal polyps. In Nasal Polyposis: Pathogenesis, Medical and Surgical Treatment. Springer Berlin Heidelberg. 2010. p. 95-101 https://doi.org/10.1007/978-3-642-11412-0_11
Kern, Eugene B. ; Sherris, David A. ; Kita, Hirohito ; Ponikau, Jens U. / Fungal-induced inflammation and nasal polyps. Nasal Polyposis: Pathogenesis, Medical and Surgical Treatment. Springer Berlin Heidelberg, 2010. pp. 95-101
@inbook{8ed7b1ab13d24b0d8242910ad48f9efb,
title = "Fungal-induced inflammation and nasal polyps",
abstract = "Fungi are present in the mucus of chronic rhinosinusitis (CRS) patients and normal healthy controls. Fungi (especially Alternaria) induce the production of cytokines (IL-13 and IL-5) crucial for the eosinophilic inflammation. This immune response occurred only in CRS patients but not in healthy controls. Fungi induce an eosinophilic tissue airway inflammation in mammals (mice), which is in contrast to a neutrophilic response to bacteria. Fungi can induce an eosinophilic airway inflammation and congestion in patients. Eosinophils, in vivo, target fungi in the mucus with CRS and nasal polyps. Fungal antigens with a molecular weight of 61 kilodaltons (kDa) cause activation and degranulation of human eosinophils via the beta-2 integrin on the CD11b receptor. Clinically, antifungal drugs can reduce nasal polyps, improve computed tomography (CT) scans, and decrease levels of interleukin-5 (IL-5) and markers of eosinophilic inflammation. However, data between different antifungal applications and different outcome measures are conflicting.",
author = "Kern, {Eugene B.} and Sherris, {David A.} and Hirohito Kita and Ponikau, {Jens U.}",
year = "2010",
doi = "10.1007/978-3-642-11412-0_11",
language = "English (US)",
isbn = "9783642114113",
pages = "95--101",
booktitle = "Nasal Polyposis: Pathogenesis, Medical and Surgical Treatment",
publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - Fungal-induced inflammation and nasal polyps

AU - Kern, Eugene B.

AU - Sherris, David A.

AU - Kita, Hirohito

AU - Ponikau, Jens U.

PY - 2010

Y1 - 2010

N2 - Fungi are present in the mucus of chronic rhinosinusitis (CRS) patients and normal healthy controls. Fungi (especially Alternaria) induce the production of cytokines (IL-13 and IL-5) crucial for the eosinophilic inflammation. This immune response occurred only in CRS patients but not in healthy controls. Fungi induce an eosinophilic tissue airway inflammation in mammals (mice), which is in contrast to a neutrophilic response to bacteria. Fungi can induce an eosinophilic airway inflammation and congestion in patients. Eosinophils, in vivo, target fungi in the mucus with CRS and nasal polyps. Fungal antigens with a molecular weight of 61 kilodaltons (kDa) cause activation and degranulation of human eosinophils via the beta-2 integrin on the CD11b receptor. Clinically, antifungal drugs can reduce nasal polyps, improve computed tomography (CT) scans, and decrease levels of interleukin-5 (IL-5) and markers of eosinophilic inflammation. However, data between different antifungal applications and different outcome measures are conflicting.

AB - Fungi are present in the mucus of chronic rhinosinusitis (CRS) patients and normal healthy controls. Fungi (especially Alternaria) induce the production of cytokines (IL-13 and IL-5) crucial for the eosinophilic inflammation. This immune response occurred only in CRS patients but not in healthy controls. Fungi induce an eosinophilic tissue airway inflammation in mammals (mice), which is in contrast to a neutrophilic response to bacteria. Fungi can induce an eosinophilic airway inflammation and congestion in patients. Eosinophils, in vivo, target fungi in the mucus with CRS and nasal polyps. Fungal antigens with a molecular weight of 61 kilodaltons (kDa) cause activation and degranulation of human eosinophils via the beta-2 integrin on the CD11b receptor. Clinically, antifungal drugs can reduce nasal polyps, improve computed tomography (CT) scans, and decrease levels of interleukin-5 (IL-5) and markers of eosinophilic inflammation. However, data between different antifungal applications and different outcome measures are conflicting.

UR - http://www.scopus.com/inward/record.url?scp=84884486026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884486026&partnerID=8YFLogxK

U2 - 10.1007/978-3-642-11412-0_11

DO - 10.1007/978-3-642-11412-0_11

M3 - Chapter

AN - SCOPUS:84884486026

SN - 9783642114113

SP - 95

EP - 101

BT - Nasal Polyposis: Pathogenesis, Medical and Surgical Treatment

PB - Springer Berlin Heidelberg

ER -